Market closed

Immunome/$IMNM

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

Ticker

$IMNM
Trading on

Industry

Biotechnology

Employees

105

Immunome Metrics

BasicAdvanced
$582M
Market cap
-
P/E ratio
-$5.69
EPS
1.82
Beta
-
Dividend rate
$582M
1.82
$30.96
$6.93
697K
6.174
6.075
1.147
1.266
-39.89%
-276.36%
49.397
2.62
2.62
-3.608
-0.62%
215.44%
44.31%

What the Analysts think about Immunome

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Immunome stock.

Immunome Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immunome Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMNM

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Immunome stock?

Immunome (IMNM) has a market cap of $582M as of November 22, 2024.

What is the P/E ratio for Immunome stock?

The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of November 22, 2024.

Does Immunome stock pay dividends?

No, Immunome (IMNM) stock does not pay dividends to its shareholders as of November 22, 2024.

When is the next Immunome dividend payment date?

Immunome (IMNM) stock does not pay dividends to its shareholders.

What is the beta indicator for Immunome?

Immunome (IMNM) has a beta rating of 1.82. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.